To assess the clinical safety and feasibility of the MaMaLoc technique: a novel magnetic localisation technique for intra-operative lesion localisation.
ID
Source
Brief title
Condition
- Breast neoplasms malignant and unspecified (incl nipple)
- Breast therapeutic procedures
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Identification rate (IR) of the magnetic marker relative to the total amount of
included subjects (percentage).
Secondary outcome
Not applicable.
Background summary
All currently available tumour localisation techniques for non-palpable breast
lesions suffer from significant disadvantages, ranging from poor accuracy
(wire-guided localisation) to low uptake due to the laborious nature of
implementing the technique (radioactive techniques).
Study objective
To assess the clinical safety and feasibility of the MaMaLoc technique: a novel
magnetic localisation technique for intra-operative lesion localisation.
Study design
The proposed study is designed as a non-blinded, non-controlled, observational
phase I study in which we assess the feasibility of a novel magnetic medical
device for the localisation of non-palpable breast lesions.
Intervention
The magnetic MaMaLoc marker is placed in or near the lesion by a radiologist,
in an already locally anesthesized area during the same session as placement of
the iodine seed. Directly prior to the start of the surgeon, a magnetic
detector is used to locate the magnetic marker. After the surgery, the marker
is confirmed present in the excised tissue using the magnetic detector as well
as the pathologist. The rest of the care process is identical to a 'standard'
iodine seed surgery.
Study burden and risks
Patient burden is limited to one extra injection at the radiology department
during a session that is conventionally used to implant a radio-active marker.
Patient risk is negligible. Detection using low-field magnetism is inherently
safe and the marker is constructed from biocompatible materials.
Plesmanlaan 121
Amsterdam 1066 CX
NL
Plesmanlaan 121
Amsterdam 1066 CX
NL
Listed location countries
Age
Inclusion criteria
* Unifocal, non-palpable breast lesion
* Treated with breast sparing surgery
* Using radio-active seed localisation (RSL)
* Age > 18 years.
Exclusion criteria
* Treated with neo-adjuvant chemotherapy
* Planned MRI in the period between marker placement and surgery
* Tumor depth >4cm
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL53399.031.15 |